TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL

Primary analysis of the TRANSFORM study: liso-cel vs SOC as second-line treatment for R/R LBCLПодробнее

TRANSFORM: Phase III study of liso-cel versus standard of care for R/R LBCLПодробнее

Matched-adjusted comparison of liso-cel versus axi-cel for the second-line treatment of R/R LBCLПодробнее

Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCLПодробнее

The value of axi-cel as a second-line treatment in R/R LBCLПодробнее

Axi-cel as second-line therapy for R/R large B-cell lymphomaПодробнее

Liso-Cel in B-Cell Lymphomas in TRANSFORM Study With Dr. KamdarПодробнее

Interim analysis of TRANSFORM: liso-cel vs SOC in high-risk R/R LBCLПодробнее

Rationale of TRANSFORM: liso-cel vs SOC in patients with high-risk R/R NHLПодробнее

Primary analysis of the Phase II PILOT study: liso-cel as second-line therapy for R/R LBCLПодробнее

ctDNA as an early outcome predictor in patients with 2L LBCL treated with liso-cel versus SoCПодробнее

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCLПодробнее

Update on TRANSFORM: liso-cel vs SOC in R/R LBCLПодробнее

Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCLПодробнее

ZUMA-7: overall survival benefit of axi-cel over SOC in second-line LBCLПодробнее

Second-line CAR-T therapy in B-cell lymphomaПодробнее

Matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2L treatment of R/R LBCLПодробнее

Choosing between tisa-cel, liso-cel & axi-cel in LBCLПодробнее

Approval of axi-cel in second-line for R/R LBCL & label updateПодробнее